in 40 children and adolescents were treated using the Leksell Gamma Knife at UCSF. A multidisciplinary team composed of neurosurgeons, radiation oncologists, diagnostic and interventional radiologists, nurses, and physicists reviewed all cases at a joint conference before selection for radiosurgery. Pediatric patients selected for gamma knife surgery were usually chosen on the basis of the location of the AVM, or the size of the original or residual lesion following previous embolization and/or surgical resection, if any. All patients younger than 18 years of age at the time of initial treatment, in whom at least 36 months of imaging and clinical follow-up data were available, were included in the present series.
Grading of AVMs
For the purposes of this retrospective study, centralized review of all pretreatment angiograms was performed by one of the authors (M.W.M.) for grading of all AVMs according to the Spetzler-Martin grading system. 28 
Radiosurgical Equipment
The Leksell gamma knife unit (Elekta Instruments, Atlanta, GA), initially installed at UCSF in 1991, was used for all radiosurgical procedures in this study. The details of this unit and its operation have been well documented. 19, 35 The gamma knife unit consists of 201 separate, shielded cobalt sources. Secondary augmentation of the primary collimation within the central body of the unit with interchangeable helmets yields a 50% isodose diameter that ranges from approximately 4 to 18 mm at the isocenter. The initial average radiation dose rate is approximately 4 Gy/minute, but this can be modified by adjusting the aperture size and it declines with time due to the 60 Co halflife of 5.3 years.
Treatment Procedure
General anesthesia was required for stereotactic frame placement and treatment in most children younger than 14 years of age to assure patient comfort, cooperation, and airway protection. 2 Most adolescents and some younger patients tolerated oral sedation and local anesthesia for frame placement. Frame placement was guided by the location of the lesion and was designed to place the AVM close to the center of the frame. Neuroimaging was performed with the appropriate modality (CT scanning, MR imaging, or angiography) after frame placement. Following imaging, the child was observed in the postanesthesia recovery room until the planning stage was completed. During the treatment period, the patient was monitored by remote video cameras while in the presence of a pediatric anesthesiologist, neurosurgeon, radiosurgery nurse specialist, radiation oncologist, and radiation oncology therapist. After completion of treatment, the stereotactic frame was removed and the patient was monitored in the postanesthesia recovery room before transfer to the neurosurgical ward.
Imaging Localization
Patients underwent neuroimaging after placement of a Leksell stereotactic frame (Elekta Instruments) with the appropriate indicator plates. In addition to CT scanning or MR imaging, standard anteroposterior and lateral angiographic images were obtained. Correlation of the angiograms and CT or MR images in stereotactic space yielded optimum volume definition of the AVM nidus in three dimensions. The target was first defined by biplanar angiography and then refined following superimposition of the angiographic target on MR (or CT) images. In most cases the final target volume was smaller than the volume previously determined angiographically.
Treatment Planning
Radiosurgical treatment planning was accomplished using a dedicated software planning package (in 1991 and 1992, the Kula plan was used; from 1993 to the present, the gamma plan has been used [both software packages were obtained from Elekta Instruments]) that allows a rapid iterative planning approach with display of isodose contours over MR images for conformal coverage of the entire AVM nidus. Most targets required treatment with multiple isocenters and variable collimator diameters. Radiation dose was prescribed to the highest isodose contour completely surrounding the target volume (usually the 50% isodose contour). The prescribed dose was adjusted on the basis of the volume enclosed by the prescription isodose contour by using the dose-volume prescription curve shown in Fig. 1 a general guideline. Lower doses tended to be prescribed for lesions in critical locations such as the brainstem, and efforts were made to limit the maximum dose delivered to the optic nerves or chiasm to 9 Gy.
Follow-Up Period
Clinical follow-up information was obtained by a review of outpatient follow-up clinic visit notes or by telephone interviews with patients and their parents. Patients underwent follow-up neuroimaging with semiannual MR imaging; if the MR imaging study was suggestive for obliteration of the AVM, a confirmatory angiogram was requested. All imaging studies were reviewed centrally to evaluate AVM response to radiosurgery and document any posttherapy changes such as T 2 prolongation. For this analysis, only patients in whom clinical and imaging follow-up examinations were performed at least 36 months posttreatment (or those in whom earlier definitive evidence of AVM obliteration had been recorded) were included in this study. Angiography reports were used to categorize responses as complete (no nidus), partial (smaller nidus), or none (no change observed since the pretreatment angiogram). Two patients in whom angiography revealed a tiny residual lesion, such as an early draining vein, underwent no further angiography or treatment, in accordance with our recommendations, and were included in the complete responder group for the remainder of the analysis. Magnetic resonance imaging and MR angiography were used to categorize responses in five patients whose families refused confirmatory angiography.
Statistical Analysis
For each AVM, the size was taken as the target volume from each gamma knife treatment plan. For the first seven cases in the series, however, Kula plans were used and target volumes were not retrospectively available from the treatment plans. The average ratio of isodose volume to target volume for the 24 known cases was applied to the first seven cases to generate an estimated target volume for those cases by using the following equation: estimated target volume = 0.75 ϫ isodose volume. A logistic regression analysis was performed to evaluate outcome (extent of obliteration) compared with target volume, prescription dose, and patient age as continuous independent variables and sex as a categorical independent variable. A multivariate logistic regression analysis was also performed to evaluate outcome compared with both target volume and dose. For the purposes of the logistic regression, the single patient in whom no angiographic response was observed was grouped with 
Results

Patient Characteristics
Between October 1991 and December 1997, 40 AVMs in 40 children were treated with the gamma knife at UCSF. Initial treatment was volume staged over two treatment sessions in two patients due to large AVM size (Spetzler-Martin Grade IV in one patient and Grade V in the other). Nine patients were either lost to follow-up review or their families refused confirmatory MR imaging or angiographic studies, leaving 31 patients (78%) for the final analysis (Table 1). The group was composed of 11 girls and 20 boys with a median patient age at the time of treatment of 11.2 years (range 3.4-17.5 years). Most patients presented with a primary episode of hemorrhage (18 patients [58%]) or onset of seizures (five patients [16%]). The remaining patients initially presented with progressive neurological deficits (10%), AVMs seen incidentally or during workups for multiple congenital abnormalities (10%), headaches (3%), or diplopia (3%). Radiosurgery was used as the primary treatment modality in 29 patients, and as an adjunct after radiosurgery had previously been performed using a linear accelerator in two patients. Nine patients underwent embolization before or in conjunction with radiosurgery. Tables 1 through 3 , and five were larger than 10 cm 3 ( Table 1) . Nineteen AVMs were hemispheric or ventricular in location and 12 were in ganglionic or midline structures (Tables 1 and 2 ). Five AVMs were categorized as Spetzler-Martin Grade II, 21 as Grade III, three as Grade IV, and two as Grade V (Table 3) .
Characteristics of the AVMs
Radiosurgical Treatment
General anesthesia was used in 12 patients (median age 7.7 years, range 3.3-12.5 years) and local anesthesia with or without sedation was used in 19 patients (median age 14.2 years, range 6.6-17.5 years). Nine patients underwent embolization before (six patients) or in conjunction with (three patients) gamma knife treatment. The mean target volume was 5.37 cm 3 and the median target volume was 1.6 cm ). The prescribed dose that was administered ranged from 12 to 19 Gy in a single treatment (mean 16.7 Gy, median 18 Gy), with the dose prescribed to the 50% isodose contour in the majority of cases (in 27 patients to the 50% prescription isodose, in two patients to the 55% isodose, and in one patient each to the 60 and 90% isodoses). The median number of isocenters used was five (range two to 12). The average hospital stay including treatment lasted 1.1 days (range 1-3 days).
Patient Outcomes
Follow-up reviews ranged from 6 to 99 months with a median of 60 months and a mean of 61.9 months. In patients included for analysis, follow-up periods shorter than 36 months only occurred in two patients in whom early AVM obliteration was confirmed by angiography. Of the 26 children who underwent confirmatory angiography during the first 3 years after radiosurgery, complete AVM obliteration was noted in seven (27%), partial responses in 18 (69%), and no response in one (4%). In two patients with partial responses only a tiny residual lesion, such as an early draining vein, was found and no further angiography or treatment was recommended. These patients are included in the complete obliteration group for the remainder of the analysis and discussion. (A sensitivity analysis in which logistic regression was repeated with those two patients categorized as having partial responses did not change the statistical conclusions of the study, and the primary planned analysis was used for the remainder of the discussion). Five patients underwent follow-up MR imaging only, which indicated AVM obliteration in two patients and partial response in three, bringing the overall obliteration rate after initial treatment to 35% (11 of 31 children). None of the children in whom complete obliteration was documented by either MR imaging or angiography, including the two patients harboring an inconsequential residual lesion shown on angiography, have experienced a subsequent hemorrhage.
Factors Associated With Obliteration
Obliteration rates correlated significantly with treatment prescription dose (p = 0.025, logistic regression analysis). Lesions treated with a radiation dose lower than 18 Gy (the median dose) were associated with an obliteration rate of 7% (one of 15 patients) compared with those treated with at least 18 Gy, which were associated with an obliteration rate of 63% (10 of 16 patients). Similar to the relationship between response and dose prescription, treatment response also correlated with AVM size, as estimated by target volume, but did not achieve statistical significance when logistic regression analysis was applied (p = 0.09). When the AVMs were subdivided by volume, obliteration rates were 53% for AVMs smaller than 3 cm 3 , 14% for AVMs 3 to 10 cm 3 , and 0% for AVMs larger than 10 cm 3 . Embolization did not seem to increase the chance of obliteration; in only two of nine children who underwent embolization was complete AVM obliteration attained within 36 months. Confounding this, however, was the fact that the median AVM volume in this subgroup was significantly larger (4.95 cm 3 ) than the group as whole (1.5 cm 3 ). Table 2 shows the breakdown of AVMs by size, location, and prescription dose with associated obliteration rates. Although the majority of obliterations occurred in hemispheric or ventricular AVMs, and only two obliterations occurred in the 12 lesions involving brainstem, midline, or ganglionic structures, this difference did not achieve statistical significance (p = 0.106, Fisher exact test). When evaluated according to SpetzlerMartin grade, no Grade IV or V AVMs were obliterated with a single treatment session, and up to 43% of Grade II and III AVMs were completely obliterated within 36 months of initial treatment (Table 3) .
Repeated Treatment
Twelve patients have since undergone repeated radiosurgery for residual AVMs with a median interval between treatments of 52 months (range 16-68 months). These patients are currently being observed with serial MR imaging; in five of the cases the lesion was obliterated according to MR imaging criteria and the patients are awaiting confirmatory angiography.
Complications of Treatment
Five patients suffered a total of eight hemorrhages during the entire follow-up period (Table 4) . One hemorrhage occurred during the 1st year, yielding a hemorrhage rate of 3.2%/patient-year in the 1st year after treatment. A cumulative total of four hemorrhages in three patients occurred during the 36-month follow-up period, yielding a hemorrhage rate of 4.3%/patient-year for the first 3 years after treatment. Four late hemorrhages occurred more than 4 years posttreatment in three patients in whom AVM obliteration was not attained by 36 months. Of these eight posttreatment hemorrhages, four occurred in two patients who initially presented with hemorrhage and four occurred in three patients who initially presented without hemorrhage. A Fisher exact test confirmed that there was no increased risk of posttreatment hemorrhage in our patients who presented with hemorrhage (p Ͼ 0.5). All hemorrhages occurred in patients in whom obliteration was not apparent on angiography.
Of the 27 patients for whom posttreatment MR imaging information was available for analysis, 10 patients had MR imaging documentation of T 2 changes after treatment, although only two were symptomatic, requiring several months of outpatient steroid treatment. These patients had received prescribed doses of 17.5 and 18.5 Gy, respectively, to AVMs measuring 6.1 and 2.5 cm 3 . A Fisher exact test did not demonstrate a correlation between the prescribed dose and the development of symptomatic edema (p Ͼ 0.5). The most significant complication directly related to treatment was a new permanent neurological deficit of hemiparesis and visual field loss from thrombosis of an anterior choroidal artery during preoperative embolization in one patient. A worsening of hemiparesis and visual field loss occurred after repeated hemorrhage in another patient, yielding an overall permanent neurological complication rate of 6%.
Discussion
The risk of hemorrhage for untreated AVMs has been estimated to be 2 to 4% per year. The attendant mortality rate has been estimated at 10%, with a 50% risk of serious neurological morbidity associated with each hemorrhage. 34 The younger the patient, the more substantial the cumulative lifetime risk of hemorrhage, thus increasing the potential benefit of early intervention in children. Microsurgery has been and remains the treatment of choice for accessible low-grade AVMs, providing an immediate cure with generally acceptable risks. Because of their location, however, some lesions are better suited to radiosurgery as the primary treatment modality. Radiosurgery may also be used to treat residual AVMs after surgical resection.
Review of Published Series
Stereotactic radiosurgery is now routinely used as primary therapy or as adjunctive treatment for the management of primary malignant 9, 21 and benign 31 intracranial tumors, metastatic disease, 7, 22 unresectable AVMs, 18, 20 and movement and pain disorders 12, 25, 31 in adults. More recently it has been increasingly applied to pediatric brain tumors and AVMs. ship between radiation dose, tissue volume, fraction size, and patient age, and the incidence of late CNS toxicity by using standard external beam radiotherapy. 5, 23, 27 Over the past decade, several groups have demonstrated efficacy in the radiosurgical treatment of pediatric AVMs. Steiner, et al., 29 reported a series of 54 children 5 to 12 years of age and 60 adolescents 13 to 17 years of age treated with radiosurgery. In the younger group, the obliteration rate was 54.8% at 1 year and 78.5% at 2 years. In the adolescent group, the obliteration rate was 56.6% at 1 year and 95.4% at 2 years. There was no recurrent hemorrhage in either group. In 1989 Levy and associates 16 documented AVM obliteration in 14 (77.8%) of 18 children and adolescents at 2 years posttreatment in response to Bragg peak radiosurgery. In that year as well, Altschuler, et al., 1 reported a series of 15 children younger than 18 months of age. Among the seven patients undergoing follow-up angiography at 1 year, complete AVM obliteration was attained in three patients and shrinkage of the lesion in an additional three patients. In 1990 Loeffler and colleagues 17 described a series of 10 pediatric AVMs treated with radiosurgery. Of the eight patients in whom 1-year angiographic follow up was available, complete obliteration was found in five (62.5%). In 1996, Humphreys and associates 11 reported a series of 160 children treated over 45 years in Toronto. Of the four children treated with radiosurgery, complete obliteration of the AVM was attained in three.
In the largest and most recent study of radiosurgical treatment of pediatric intracranial AVMs, the authors described a group of 53 children with at least 36 months of imaging and clinical monitoring. 15 In that study, Levy and associates emphasized the relationship between AVM volume and obliteration rate, reporting an 80% obliteration rate for AVMs smaller than 3 cm 3 , 64% for AVMs 3 to 10 cm 3 , and 0% for AVMs larger than 10 cm 3 . They reported that volume was the only statistically significant variable correlating with obliteration rates when multivariate logistic regression analysis was applied. Their overall obliteration rate after a single gamma knife treatment session was 59%.
The results from the current study are also consistent with the relationship between AVM obliteration and volume reported by Levy and associates. The obliteration rate in the current series was 53% for AVMs smaller than 3 cm 3 (19 patients), 14% for AVMs 3 to 10 cm 3 (seven patients), and 0% for AVMs larger than 10 cm 3 (five patients), although this correlation did not achieve significance when logistic regression analysis was applied.
Treatment and Outcomes
In this study we report a lower overall rate of AVM obliteration by using radiosurgical techniques in children than that reported in the literature for adults. We attribute this difference to the conservative dose prescriptions delivered to AVMs in children to minimize the CNS toxicity of radiation on the developing brain and the relatively large size of AVMs treated in our series (12 of 31 patients harbored AVMs with target volumes Ͼ 5 cm 3 ). In the recent pediatric series treated in Pittsburgh, for example, there was a much higher obliteration rate, but the group's AVM volume was small, with only one lesion larger than 10 cm 3 (median size 1.7 cm 3 , range 0.11-10.2 cm 3 ), and the median marginal dose prescribed was greater (20 Gy). The correlation between AVM size and obliteration rate did not achieve statistical significance in the current study, but there was a significant correlation between dose prescription and obliteration rate (p = 0.025). Specifically, in the present series, when at least 18 Gy was delivered, either in a single or staged fashion, obliteration rates increased nearly 10-fold over those of lesions receiving less than 18 Gy (63% compared with 6.6%). The larger lesions were most probably refractory to treatment because lower doses were prescribed to avoid radiation injury to the larger volume of surrounding normal brain structures. This is demonstrated in Fig. 1 ; the fact that some larger lesions received adequate dose prescriptions, whereas others did not, helps explain why a statistically significant correlation between response and AVM size was not seen. Treatment of larger lesions was confounded by increased conservatism in dose prescription, resulting in a number of patients treated at doses below the dose-volume prescription relationship that predicts an approximate 3% risk of permanent neurological injury (Fig. 1  lower) .
It is reasonable to hypothesize that the radiobiological response to treatment at the level of the vessel is likely to be the same in large and small AVMs and, thus, that a favorable response to radiosurgery should be expected as long as a sufficient dose-one exceeding the threshold for vessel involution-is reached, regardless of overall AVM size. This concept is supported by a report by Yamamoto, et al., 36 that even large AVMs with volumes up to 30 cm 3 can be obliterated (75% of cases) when a marginal dose of at least 16 Gy is used. Furthermore, they reported that the obliteration rate for larger AVMs (11-30 cm 3 ) treated with 16 to 18 Gy was similar to that for smaller AVMs (Ͻ 10 cm 3 ) treated with 18 to 20 Gy. Therefore, the reason for poor obliteration rates in larger AVMs may not be related so much to their size, but to the limitations of dosing a larger nidus volume with a larger volume of normal surrounding brain, while striving to keep the risk of radiation-induced CNS toxicity the same. Techniques used to increase radiation delivery to the AVM nidus, such as hypofractionated or volume-staged treatments, may play a substantial role in improving obliteration rates in larger, inoperable, and risky AVMs. We have begun to use adult dose prescriptions initially in treating similar AVMs in children to increase the chances of obliteration and reduce the interval during which the child remains vulnerable to hemorrhage.
Complications of Treatment
Complication rates in this series were similar to those published in a recent large multiinstitutional analysis of complications after AVM radiosurgery in 1255 patients 6 ( Table 4 ). The most serious complications were recurrent hemorrhage within the interval between treatment and obliteration, one of which resulted in a significantly worsened hemiparesis and visual field loss. A major new neurological deficit related to a pretreatment embolization procedure occurred in one (11%) of nine patients who underwent embolization. On 37% of posttreatment MR images T 2 changes were observed, a rate similar to that reported by Flickinger and associates 6 (30%). Despite receiving marginal doses near the median dose, two patients experienced symptomatic brain edema requiring outpatient steroid treatment (6.5% in our series compared with 4.8% in the series treated by Flickinger and associates).
